7 March 2016 - AstraZeneca today announced that its global biologics research and development arm, MedImmune, has received Fast Track designation from the US FDA for its investigational human monoclonal antibody, MEDI8852, for the treatment of patients hospitalised with Type A strain influenza.

For more details, go to: https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/Medimmune-receives-fast-track-designation-in-the-US-for-MEDI8852-for-treatment-of-patients-hospitalised-with-influenza-A-07032016.html